

Ref. No. JPL/CS/1722/2021

To
The BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Date: 02nd August, 2021Reg.: **Regulation 34 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015.**Sub. : **Annual Report 2020-21.**

Dear Sir,

Kindly find attached the soft copy of the Annual Report of the Company, pertaining to financial year 2020-21 inter-alia containing followings:

1. Notice convening 36th Annual General Meeting, which will be held on Tuesday, 07th September, 2021 at 3.30 p.m. through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). The notice also contain the instructions for e-voting;
2. Audited financial statements for the financial year 2020-21 in accordance to IND-AS, with notes thereto;
3. Cash flow statements in accordance to IND-AS;
4. Directors' report thereon with annexures;
5. Management discussion and analysis report, as a part of directors' report;
6. Auditors' report with unmodified opinion;
7. Report on Corporate Governance.


Only soft copies of this Annual Report are being e-mailed to the eligible shareholders of the Company in pursuance to the Ministry of Corporate Affairs's Circulars No. 02/2021 dated 13th January, 2021, read with MCA's circular No No.20/ 2020 dated 5th May 2020, 14/ 2020 dated 8th April 2020, No. 17/2020 dated 13th April 2020, and SEBI's circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated 15th January, 2021 read with its earlier circular no. SEBI/HO/CFD/CMD1/CIR/P/2020/79, dated 12th May, 2020.

A copy of annual report is also available on the website of the Company. viz. www.jenburkt.com.

Kindly take on record the above.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Limited



Ashish R. Shah
Company Secretary and Compliance Officer

Encl.: As Stated Above.

 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 

2021 Annual Report



HERE TO HEAL

Committed to healing the nation



Our Guiding Philosophy



WHO WE ARE

Our purpose at Jenburkt Pharmaceuticals Ltd. is to serve those in need of quality healthcare by bringing revolutionary, life-changing therapeutic solutions that are accessible to all. We believe in serving our patients - through them we serve God, Humanity and Nation.

MISSION

We wish to serve our patients, through them serve God, Humanity and Nation. Nothing gratifies us more than bringing a smile to our patients' face.

VISION

To instill trust in life sciences through delivering excellence by weaving together in-depth research, efficient use of resources and capital and unparalleled knowledge to build speciality, high-quality pharmaceutical formulations and healthcare products that bring positive change and health safety to families around the world.

SERVING THE NATION IN THE TIME OF NEED

2020 was an extraordinary year by any measure with COVID-19 enveloping us all in dread and despair.

Watching the number of cases rise steeply in India, all of us at Jenburkt were sincerely focused on what we, as a pharmaceutical company with a rich history of giving back and innovation, could do to truly serve our nation at this time of dire need.

This is why - in July 2020, Jenburkt became the second in the country to announce the launch of antiviral drug Favipiravir (brand name Favivent™) for the treatment of mild to moderate COVID-19 symptoms at the most affordable price, at that time, of Rs. 39/- per tablet.

Not just was this covered exceedingly favourably by mainstream media and regional news outlets, the public championed

Favivent and our conscious effort to keep the price reasonable to ensure maximum access. In fact, our competitive pricing set the tone for a price war with the industry incumbent, and paved the path for affordable pricing for others in the market - not just for the 200mg variant, but also 400mg & 800mg. We went a step ahead and even appreciated the affordable pricing of the product launched by a competing brand on social media - a move that was appreciated deeply by the public.

In the past one year, we have distributed packs of Favivent across the worst-hit cities in India and contributed to the recovery of thousands of patients and families across the country.

We went a step ahead and also donated INR 72 Lacs + worth of the medicine to certified health institutions, listed Favivent stock availability on our new-website so individuals had real-time visibility per city and also deepened our relationships with India's most experienced doctors in the field via a Knowledge Series of webinars.

We are incredibly proud of what our company and our exemplary team members around the world achieved, collectively and individually this past year, staring bravely in the face of the greatest health threat looming over us.

Just as our heart goes out to everyone affected by COVID-19, we bow our heads in gratitude to our first responders and medical professionals who are risking their lives every single day to keep us safe. They are the true heroes of this crisis, and their intrepid actions are an inspiration to us all at Jenburkt.



- We are proud to share that we are the **second in India** to introduce **high-quality antiviral Favipiravir (brand name FAVIVENT)** for mild to moderate COVID-19 symptoms.
- Manufactured at a US-FDA and EDQM compliant plant with the strictest safety and manufacturing protocols in place.

LAUNCHED AT A VERY AFFORDABLE PRICE TO SERVE THE NATION IN THIS TIME OF NEED!

Rs. 39 / tablet

**For the use of a registered medical practitioner only.*



In July 2020, we launched **FAVIVENT** (antiviral drug Favipiravir) for mild to moderate COVID-19 symptoms at a very affordable price of **MRP Rs. 39/tablet** to **serve the nation!**



*Prescription-only Medicine to be administered in prescribed dosage under a certified medical practitioner's supervision. For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory only.

WE WON

THE AWARD OF PHARMA EXCELLENCE 2020
for Covid Medical Education Initiatives!



"Given the current scenario of grave health concerns and economic challenges surrounding COVID-19 in India, if we as a pharmaceutical company cannot make a significant positive difference to the society, our company's very existence is inconsequential"

Mr. Ashish U Bhuta
Chairman and MD
Jenburkt Pharmaceuticals Ltd

Our continuous efforts to **serve the nation** by launching **Favivent** at Rs. 39/tablet at this time of need, and educating doctors across the country on Favipiravir are being recognized! Thank you for supporting us!



Excellent Quality with Affordable Price

PROUDLY INTRODUCING

Favivent

Favipiravir 200 mg Tablets


Vents out COVID-19.. **Effectively**

For adults with mild-to-moderate **COVID-19**

Price = Rs.39 per tablet

Manufactured at a   Manufacturing plant

*DCGI Approved oral antiviral in Mild to Moderate COVID -19



Dr Ivary ramuk @ivark2008 . 4d

@JenburktPharma thank you lot for your effort to release covid drug at reasonable price. This shows you are more people friendly and money conscious at these tough times



biswajit dash @Ar_BiswajitDash . 5d
Replying to @snehamordani
@jenburktPharma and @CNNnews18

good going guys... keep up the place..entire country will proud of you..



Dr Deepali Bhardwaj
@dermatdoc

Excellent news tablet #favivent Rs39/- announced by Company called jenburkt which gave a jolt to #fabiflu priced at 75/- by #GLENMARK so Cost of #Covid_19 therapy comes down from 13-14k to half in India #COVID19_BREAKING Hoping everyone should get access to possible treatments.



Satyendradev Mahanti
@MahantiSd

Excellent move by Jenburkt.

PRODUCT LAUNCH MEDIA COVERAGE

The Favivent product launch has been covered by close to 100 publications across the country in just a few days of launch!

Business Today **Business Standard** **FINANCE REWIND** **NewsrapIndia**

live mint **NEWS 18** **LATESTLY** **INDIA TV**

INVENTIVA **UNI** **United News of India** **THE HINDU**
BREVITY ACCURACY SPEED India's Multi Lingual News Agency INDIA'S NATIONAL NEWSPAPER SINCE 1878

FINANCIAL EXPRESS **Business Today** **BW BUSINESSWORLD**
Read to Lead

EQUITY B BULLS **The New York Times** **DH DECCAN HERALD**

GSTV **yahoo! news** **GO INDIA NEWS** **asianet news हिन्दी**
देश की धड़कन

INA **पंजाब केसरी** **Newzz** **SME STREET** **ZOOM News**
Latest news from trusted sources

ZEE २४ घण्टे **CG TOP 36** **GLOBAL FINANCIAL MARKET REVIEW**
www.cgtop36.com Only Sense, No Nonsense

NDTV PROFIT **WION** **The WB Mirror**

We've gone digital!

We are delighted to announce that we have launched an all-new website and are now active on leading social media platforms!

FOLLOW, LIKE & SHARE

www.jenburkt.com


[✉ info@jenburkt.com](mailto:info@jenburkt.com)

[☎ +91 22 67603603](tel:+912267603603)

[in](#) [f](#) /jenburkt

[@jenburktpharma](#)

bit.ly/JenburktYoutube



Making It Easier to Get Affordable, Life-Saving Medications to Patients Across India with SAP S/4HANA




At Jenburkt, our Intent and Focus is on **processes and adopting** Technology across all departments.

We have reliable System driven processes set up and adopting the latest technology like the latest version of SAP S/4HANA and SAP BusinessObjects business intelligence solutions. We have benefited from their tight, native integration between processes, industry depth, and a consistent in-memory data model.

We have used these digital tools to simplify complex processes and improve operational efficiency and visibility, especially in batch-tracing and inventory management. Additionally, it has helped us analyze sales and performance by product and region for medical representatives across the country.

In the past year, a case study on our usage of SAP S/4 Hana featured on the SAP global website as well as their social media channels.



Founders

Board of Directors

Company Secretary

Auditors

Bankers

Registered Office

Plant

Research & Development Centre

Registrar & Transfer Agents

Index



Notice

Notice

and conditions of the Whole Time Director's appointment and payment of remuneration within the overall limit as stated in explanatory statement, subject to the applicable provisions of the Act, any rules made thereunder and provisions of Schedule V of the Act (including any alterations / modifications, if any, thereof for the time being in force).

RESOLVED FURTHER THAT in the event of a loss or inadequacy of the profit of the Company in any financial year during his tenure, the proposed remuneration shall be paid to the Whole Time Director as a minimum remuneration, for the period of three years, from 1st April, 2022 till 31st March, 2025, subject to all applicable provisions of the Act, any rules made thereunder and Schedule V of the Act (including any alterations / modifications, if any, thereof for the time being in force).

RESOLVED FURTHER THAT the Board be and is hereby authorized to enter into an employment agreement with the Whole Time Director, specifying all the terms and conditions of employment, and do all such acts, deeds, things, as they may in their absolute discretion consider necessary and appropriate to give effect to this resolution”.

4. To consider and if thought fit, to pass the following resolution, as a Special Resolution:

“RESOLVED THAT pursuant to the Sections 196, 197, 203, and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 any other rules made thereunder, read with Schedule V and all other applicable provisions of the Companies Act 2013 (“the Act”), including any statutory alterations, modifications or re-enactments thereof, for the time being in force, the applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and subject to all such other approvals as may be required, the consent of the Members be and is hereby accorded for the re-appointment of Shri Dilip H. Bhuta (DIN-03157252), as the Whole Time Director, designated as the Whole Time Director and Chief Financial Officer (CFO) of the Company, whose terms of office shall be liable to retire by rotation, for a period of five (5) Years with effect from 1st April, 2022 till 31st March, 2027, including terms of remuneration, for a period of three (3) years, from 1st April, 2022 till 31st March, 2025, on the terms and conditions as set out in the Explanatory Statement annexed to the Notice convening this meeting.

RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as “the Board” which term shall include the Nomination and Remuneration Committee of the Board) be and is hereby authorised and empowered in their absolute discretion to change, alter or modify the terms

5. To consider and if thought fit, to pass the following resolution, as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 148 and all other applicable provisions of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 including any statutory modifications or re-enactments thereof for the time being in force, the remuneration payable for the financial year ending 31st March, 2022 to M/s Jagdish R. Bhavsar, Cost Accountants, (Firm Registration No. 102167), appointed by the Board of Directors of the Company to conduct the audit of the Cost Records of the Company, amounting to 2,15,000 (Rupees Two Lakhs Fifteen Thousand) be and is hereby ratified and confirmed.

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorized to do all such acts and take appropriate steps as may be necessary and proper to give effect to this resolution.”

| Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical | Your User ID is: |
|--|------------------|
| | |
| | |
| | |

Annexure to the Notice

EXPLANATORY STATEMENT

Pursuant to Section 102(1) of the Companies Act, 2013 (the Act), setting out all material facts relating to the Special Business:

For item number 4 of the Notice:

Shri Dilip H. Bhuta, (DIN:03157252), designated as the Whole Time Director and Chief Financial Officer (CFO) of the Company was appointed for a period of three years from 1st April, 2019 to 31st March, 2022, by the members at the 33rd AGM held on 31st July, 2018. His remuneration for the said period was also approved simultaneously.

The Board of Directors of the Company, on the recommendation of the Nomination and Remuneration Committee, vide their respective meetings held on 02nd June, 2021, subject to the approval of the members of the Company, re-appointed Shri Dilip H. Bhuta as the Whole Time Director of the Company, for a period of five years from 1st April, 2022 to 31st March, 2027, with terms of his remuneration for a period of three years from 1st April, 2022 to 31st March, 2025.

The Nomination and Remuneration Committee and the Board, considering his expertise, knowledge and broad experience in the field of Finance and other relevant aspects of the operations of the Company and long business experience, recommended and decided that the continued association of Shri Dilip H. Bhuta would be of immense benefit to the Company for the smooth and efficient running of the business. It is also desirable in the best interest of the Company to continue to avail his services as the Whole Time Director and CFO and KMP of the Company.

The terms of proposed remuneration of Shri Dilip H. Bhuta is as set out below:

- a) Remuneration: salary, perquisites and allowances per annum (maximum from 1st April, 2022 to 31st March, 2025):

| Particulars | (₹ in Lacs) |
|-------------|-------------|
| | |
| | |
| | |

- b) The perquisites and allowances, shall include house rent allowance together with reimbursement of expenses and / or allowances, medical assistance and leave travel concession for self and family including dependents. The said perquisites and allowances shall be evaluated, wherever applicable, as per the provisions of Income Tax Act, 1961 or any other rules or standards, in this regards, or any rules thereunder or any statutory modification(s) or re-enactment(s) thereof; in the absence of any such standards, rules, etc., the perquisites and allowances shall be evaluated at actual cost.
- c) A car with service of driver for official use shall be provided by the Company which shall be in addition to the remuneration under (a) above.

- d) Increment in salary, perquisites and allowances payable to Shri Dilip H. Bhuta, as may be determined by the Board and / or the Nomination and Remuneration Committee of the Board, within the overall limit of remuneration stated under (a) above.
- e) Reimbursement of Expenses: Expenses incurred for travelling, boarding and lodging during business trips and provision of car(s) for use for Company's business and other conveyance expenses shall be reimbursed at actual and shall not be considered as perquisites.

The following perquisites, however, shall not be included in the computation of the ceiling on remuneration: (a) Contribution to Provident Fund, Superannuation Fund or Annuity Fund to the extent that these either singly or put together are not taxable under the Income Tax Act, 1961; (b) Gratuity payable under the payment of Gratuity Act, 1972 and (c) Encashment of leave.

| Particulars | (₹ In Lacs) |
|-------------|-------------|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |



Directors' Report

Directors' Report

| Particulars | Year ended 31 st March, 2021 | Year ended 31 st March, 2020 |
|-------------|---|---|
| | 10,929.42 | |
| | 430.85 | |
| | 9,196.10 | |
| | 2,164.17 | |
| | 513.93 | |
| | 1,650.24 | |
| | 195.96 | |
| | 1,846.20 | |
| | 35.96 | |
| | 9,387.69 | |

Annexure A

FORM NO. MR-3 SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2021

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014] UDIN: F004554C000413512

To
The Members,
JENBURKT PHARMACEUTICALS LIMITED
Nirmala Apartments, 93, Jay Prakash Road, Andheri (West), Mumbai 400 058.

Dear Sir / Madam,

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good Corporate Governance practice by **Jenburkt Pharmaceuticals Limited** (hereinafter called "**the Company**"). The Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company, the information as provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit in physical form and electronic form, the explanations and clarifications given to us and the representations made by the Management and also considering the relaxations granted by the Ministry of Corporate Affairs and the Securities and Exchange Board of India ("SEBI") due to the spread of the Covid-19 pandemic, we hereby report that in our opinion, the Company has during the audit period covering the financial year ended on 31st March, 2021, generally complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We herewith report that maintenance of proper and updated Books, Papers, Minutes Books, filing of Forms and Returns with applicable regulatory authorities and maintaining other records including fully functional website is responsibility of management and of the Company. Our responsibility is to verify the content of the documents produced before us, make objective evaluation of the content in respect of compliance and report thereon. We have examined on test check basis, the books, papers, minute books, forms and returns filed and other records maintained by the Company and produced before us for the financial year ended 31st March, 2021, as per the provisions of:

- (i) The Companies Act, 2013 and the rules made there under;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under (to the extent applicable to the Company);
- (iv) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client;
 - (d) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015;

We have in-principally verified systems and mechanism which is in place and followed by the Company to ensure Compliance of the following specifically applicable Laws / Orders (in addition to the above mentioned Laws (i to iv) and applicable to the Company since the Company is engaged in dealing of Pharmaceutical products) and we have also relied on the representation made by the Company and its Officers in respect of systems and mechanism formed / followed by the Company for compliances of other applicable Acts, Laws and Regulations and found the satisfactory operation of the same.

- Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics (6th Amendments) Rules, 2016
- The Drug (Price Control) Order, 2013
- Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954

'ANNEXURE -1'
UDIN: F004554C000413512

Annexure B

Form No. MGT 9: Extract of Annual Return as on Financial Year ended on 31st March, 2021

[Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company (Management & Administration) Rules, 2014.]

I. Registration & Other Details:

| | | |
|---|--|---|
| 1 | CIN | L24230MH1985PLC036541 |
| 2 | Registration Date | 10 th June, 1985. |
| 3 | Name of the Company | Jenburkt Pharmaceuticals Limited |
| 4 | Category/Sub-category of the Company | Company Limited by Shares/ Indian Non-Government Company |
| 5 | Address of the Registered office & contact details | Nirmala Apts., 93, J.P.Road, Andheri West, Mumbai-400058. Tel. No.:+91-22-66943121 Fax No.:91 22 66943127, e-mail:investor@jenburkt.com web site: www.jenburkt.com |
| 6 | Whether listed company | Yes, Listed at BSE Ltd., INDIA. |
| 7 | Name, Address & contact details of the Registrar & Transfer Agent, if any. | Bigshare Services Pvt. Ltd., 1 st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri (E), Mumbai – 400 059. Tel. No. 91-22-62638200 Fax No.:91-22-6263 8299, e-mail: ujata@bigshareonline.com |

II. Principal Business Activities of the Company:

(All the business activities contributing 10 % or more of the total turnover of the Company)

| | NIC Code of the Product/service | % to total turnover of the Company |
|--------------------------------|---------------------------------|------------------------------------|
| 1. Pharmaceuticals Formulation | 21002 | 100 |

III. Particulars of Holding, Subsidiary & Associate Companies

| Sr. No. | Name and address of the Company | CIN/GLN | Holding/ Subsidiary/ Associate | % of shares held | Applicable Section |
|---------|---------------------------------|---------|-----------------------------------|---------------------|-----------------------|
| 1 | N. A. | | | | |

| Particulars | Secured Loans excluding deposits | Unsecured Loans | Deposits | Total Indebtedness |
|--|-------------------------------------|--------------------|----------|-----------------------|
| Indebtedness at the beginning of the financial year | | | | |
| i) Principal Amount | 342.31 | 290.84 | - | 633.15 |
| ii) Interest due but not paid | - | 42.44 | - | 42.44 |
| iii) Interest accrued but not due | - | - | - | - |
| Total (i+ii+iii) | 342.31 | 333.28 | - | 675.59 |
| Change in indebtedness during the financial year | | | | |
| Addition to Loans | 5,502.00 | 5.63 | - | 5,508.27 |
| Addition to Interest | - | 24.72 | - | 36.67 |
| Reduction of Loans | 5,477.82 | - | - | 5,477.82 |
| Reduction of Interest | - | 18.62 | - | 18.62 |
| Net Change | 24.81 | 11.72 | - | 36.54 |
| Indebtedness at the end of the financial year | | | | |
| i) Principal Amount | 367.12 | 296.47 | - | 663.59 |
| ii) Interest due but not paid | - | 48.53 | - | 48.53 |
| iii) Interest accrued but not due | - | - | - | - |
| Total (i+ii+iii) | 367.12 | 345.00 | - | 712.12 |

| Category of Shareholders | No. of Shares held at the beginning of the year [As on 1-April-2020] | | | | No. of Shares held at the end of the year [As on 31-March-2021] | | | | % change during the year |
|--------------------------|---|----------|-----------|-------------------|--|----------|-----------|-------------------|--------------------------|
| | Demat | Physical | Total | % of Total Shares | Demat | Physical | Total | % of Total Shares | |
| | | | | | 14,82,660 | - | 14,82,660 | 32.31 | |
| | | | | | - | - | - | - | |
| | | | | | 6,16,128 | - | 6,16,128 | 13.43 | |
| | | | | | - | - | - | - | |
| | | | | | 20,98,788 | - | 20,98,788 | 45.73 | |
| | | | | | - | - | - | - | |
| | | | | | - | - | - | - | |
| TOTAL (A) | 20,98,788 | - | 20,98,788 | 45.73 | 20,98,788 | - | 20,98,788 | 45.73 | 0.00 |
| | | | | | 1,17,809 | - | 1,17,809 | 2.57 | |
| | | | | | - | - | - | - | |
| | | | | | 1,17,809 | - | 1,17,809 | 2.57 | |
| | | | | | - | - | - | - | |
| | | | | | 97,840 | 1,100 | 98,940 | 2.16 | |
| | | | | | - | - | - | - | |
| | | | | | 11,93,264 | 1,49,820 | 13,43,084 | 29.27 | |
| | | | | | 6,90,008 | - | 6,90,008 | 15.03 | |
| | | | | | 97,869 | 3,000 | 1,00,869 | 2.20 | |
| | | | | | - | - | - | - | |
| | | | | | - | - | - | - | |
| | | | | | 9,572 | - | 9,572 | 0.21 | |
| | | | | | - | - | - | - | |
| | | | | | 70,281 | - | 70,281 | 1.53 | |
| | | | | | 4,043 | - | 4,043 | 0.09 | |
| | | | | | 55,984 | - | 55,984 | 1.22 | |
| | | | | | 22,18,861 | 1,53,920 | 23,72,781 | 51.70 | |
| TOTAL PUBLIC (B) | 23,10,270 | 1,80,320 | 24,90,590 | 54.27 | 23,36,670 | 1,53,920 | 24,90,590 | 54.27 | 0.00 |
| Grand Total (A+B+C) | 44,09,058 | 1,80,320 | 45,89,378 | 100.00 | 44,35,458 | 1,53,920 | 45,89,378 | 100.00 | 0.00 |

| Sr. No. | Shareholder's Name | Shareholding at the beginning of the year | | | Shareholding at the end of the year | | | % change in share holding during the year |
|---------|--------------------|---|----------------------------------|--|-------------------------------------|----------------------------------|--|---|
| | | No. of shares | % of total shares of the Company | % of shares pledged / encumbered to total shares | No. of shares | % of total shares of the Company | % of shares pledged / encumbered to total shares | |
| | | | | | 2,61,127 | 5.69 | - | |
| | | | | | 1,17,650 | 2.56 | - | |
| | | | | | 51,637 | 1.13 | - | |
| | | | | | 6,16,128 | 13.43 | - | |
| | | | | | 5,36,480 | 11.69 | - | |
| | | | | | 3,99,700 | 8.71 | - | |
| | | | | | 51,278 | 1.12 | - | |
| | | | | | 44,962 | 0.98 | - | |
| | | | | | 2,826 | 0.06 | - | |
| | | | | | 17,000 | 0.37 | - | |
| | TOTAL | 20,98,788 | 45.73 | | 20,98,788 | 45.73 | - | 0.00 |

| Sr. No. | Particulars | Shareholding at the beginning of the year | | Cumulative Shareholding during the year | |
|---------|-------------|---|-------------------|---|-------------------|
| | | No. of shares | % of total shares | No. of shares | % of total shares |
| | | | | | |
| | | | | | |
| | | | | | |

| Sr. No. | Name of the shareholders | Shareholding at the beginning of the year | | Cumulative Shareholding during the year | |
|---------|--------------------------|---|-------------------|---|-------------------|
| | | No. of shares | % of total shares | No. of shares | % of total shares |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Sr. No. | Name of Directors and Key Managerial Personnel | Shareholding at the beginning of the year | | Cumulative Shareholding during the year | |
|---------|--|---|-------------------|---|-------------------|
| | | No. of shares | % of total shares | No. of shares | % of total shares |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Sr. No. | Particulars of Remuneration | Name and Designation | | Total Amount ₹ in lac |
|---------|-----------------------------|------------------------------------|-----------------------------|-----------------------|
| | | Ashish U. Bhuta Chairman & M.D. | Dilip H. Bhuta WTD & CFO | |
| | | | | |
| | Total (A) | 147.04 | 45.74 | 192.78 |

| Sr. No. | Particulars of Remuneration | Name of Directors | | | | Total Amount (₹) |
|---------|-------------------------------------|----------------------|-----------------|------------|---------------|------------------|
| | | Arun R. Raskapurwala | Bharat V. Bhate | R. J. Vora | Hina R. Mehta | |
| | | | | | | |
| | Total Managerial Remuneration (A+B) | | | | | 196.03 |

| Sr. No. | Particulars of Remuneration | Name and Designation | | | Total Amount ₹ in lac |
|---------|-----------------------------|------------------------|-----------------------|-------------------------------------|--------------------------|
| | | Ashish U. Bhuta CMD | Dilip H. Bhuta CFO | Ashish R. Shah Company Secretary | |
| | | | | | |
| | Total | - | - | 33.20 | 33.20 |

Annexure C

| Name of the Related Party and Relationship | Nature of Contract | Duration | Salient Terms | Aggregate Amount |
|--|--------------------|----------|---------------|------------------|
| | | | | |

Annexure D

Report on Corporate Social Responsibility (CSR) for the Financial Year 2020-21.

1. A brief outline of the Company's CSR Policy:

The Company was involved, in its own way, into social responsibilities, prior to the mandatory CSR provisions came into effect, by way of statute. Your Company believe in philanthropy i.e. giving back to the society and this culture has been inculcated by its promoters viz. Bhuta family. Based on these principles a CSR policy of the Company was framed, in pursuance of the applicable provisions of the Companies Act, 2013. The CSR Committee of the Company identifies the project to be funded under CSR, preferably in and around the local area of its registered office and plant and after careful analysis the committee recommend its proposal to the Board for their consideration and decision thereon. The Board takes final decision about sanctioning the proposal and fund to be spent as CSR, in terms of the provision of the Companies Act, 2013, the Companies (Corporate Social responsibility Policy) Rules, 2014 and the Company's policy on CSR.

2. Composition of CSR committee:

| Sr. No | Name of Director | Designation / Nature of Directorship | No. of Meetings in F.Y. 2020-21 | |
|--------|------------------|--------------------------------------|---------------------------------|----------|
| | | | Held | Attended |
| | | | | |
| | | | | |
| | | | | |

3. Kindly refer to web-link: http://www.jenburkt.com/Other_Info/20152016/Policy%20on%20CSR.pdf for the Composition of CSR committee, Company's policy on CSR and details of the CSR projects approved by the board. Kindly refer corporate governance section for further details regarding CSR Committee, its role etc.

4. The details of impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable: N.A.

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any:

| Financial Year | Amount available for set-off from preceding financial years | Amount required to be set-off for the financial year, if any |
|----------------|---|--|
| | | |

6. Average net profit of the Company for last three financial years for the purpose of computation of CSR: 2,441.70 Lacs

| | |
|--|------------|
| 7. (a) Prescribed CSR expenditure (two percent of the amount as in item 6 above): | 48.83 Lacs |
| (b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years: | Nil |
| (c) Amount required to be set off for the financial year, if any: | Nil |
| (d) Total CSR obligation for the financial year (7a+7b-7c): | 48.83 Lacs |

8. (a) CSR amount spent or unspent for the financial year 2020-21:

(₹ in Lacs)

| Total Amount Spent for the Financial Year. (₹) | Amount Unspent (₹) | | | | |
|--|---|------------------|--|--------|------------------|
| | Total Amount transferred to Unspent CSR Account as per section 135(6) | | Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5). | | |
| | Amount | Date of transfer | Name of the Fund | Amount | Date of transfer |
| 94.82 | Nil | - | - | Nil | - |

(b) Details of CSR amount spent against ongoing projects for the financial year:

(₹ in Lacs)

| Sr. No | Name of the Project | Item from the list of activities in Schedule VII to the Act | Local Area (Yes/No) | Location of the project (State and District) | Project duration | Amount allocated for the project (₹) | Amount spent in the current financial Year (₹) | Amount transferred to Unspent CSR Account for the project as per Section 135(6) (₹) | Mode of Implementation - Direct (Yes/No) | Mode of Implementation - Through Implementing Agency | |
|--------|--|--|---------------------|--|------------------|--------------------------------------|--|---|--|--|-------------------------|
| | | | | | | | | | | Name | CSR Registration number |
| 1 | To set up a Blood Bank in Bhavanagar, Gujarat, by the Indian Redcross Society, Bhavanagar. | Promoting healthcare including preventive healthcare, measures for reducing inequalities faced by socially and economically backward groups. | Yes | Bhavnagar, Gujarat | more than a year | 51.00 | 22.00 | Nil | Direct | NA | NA |
| Total | | | | | | 51.00 | 22.00 | | | | |

(c) Details of CSR amount spent against other than ongoing projects for the financial year:

| Sr. No | Name of the Project | Item from the list of activities in Schedule VII to the Act | Local Area (Yes/No) | Location of the project | | Amount spent for the project (₹) | Mode of Implementation - Direct (Yes/No) | Mode of Implementation - Through Implementing Agency | |
|-----------------------------|---|--|---------------------|-------------------------|-----------|----------------------------------|--|--|-------------------------|
| | | | | State | District | | | Name | CSR Registration number |
| 1. | To distribute mask to poor, by the Indian Redcross Society, Bhavanagar | Promoting healthcare including preventive healthcare, measures for reducing inequalities faced by socially and economically backward groups. | Yes | Gujarat | Bhavnagar | 1.20 | Direct | NA | NA |
| 2. | To donate medicines for treatment of Covid-19 patients, to government run hospitals in Maharashtra and Gujarat. | Promoting healthcare including preventive healthcare, measures for reducing inequalities faced by socially and economically backward groups. | Yes | Maharashtra and Gujarat | | 71.39 | Direct | NA | NA |
| 3. | To fund tree plantation by Shree Jagdishwara Nandji Primary School, Sihor. | Ensuring environmental sustainability, ecological balance, protection of flora and fauna. | Yes | Gujarat | Bhavnagar | 0.21 | Direct | NA | NA |
| 4. | To fund tree plantation by Chabutra Ground, near Company's plant at Sihor. | Ensuring environmental sustainability, ecological balance, protection of flora and fauna | Yes | Gujarat | Bhavnagar | 0.02 | Direct | NA | NA |
| Total | | | | | | 72.82 | | | |
| Total of 8(b) + 8(c) | | | | | | 94.82 | | | |

- (d) Amount spent in Administrative Overheads : Nil
(e) Amount spent on Impact Assessment, if applicable : Nil
(f) Total amount spent for the Financial Year (8b+8c+8d+8e): 94.82 Lacs
(g) Excess amount for set off, if any: 45.99 Lacs

(₹ in Lacs)

| Sr. No | Particular | Amount (₹) |
|--------|------------|------------|
| | | |
| | | |
| | | |

9. (a) Details of Unspent CSR amount for the preceding three financial years:

| Sr. No | Preceding Financial Year | Amount transferred to Unspent CSR Account for the project as per Section 135(6) (-) | Amount spent in the reporting Financial Year (in ₹) | Amount transferred to any fund specified under Schedule VII as per section 135(6), if any. | | | Amount remaining to be spent in succeeding financial years. (-) |
|--------|--------------------------|---|---|--|---------------|------------------|---|
| | | | | Name of the Fund | Amount (in ₹) | Date of transfer | |
| 1 | | Nil | Nil | | Nil | | Nil |
| | Total | Nil | Nil | | Nil | | Nil |

- (b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s):

| Sr. No | Project ID | Name of the Project | Financial Year in which the project was commenced | Project duration | Total amount allocated for the project (₹) | Amount spent on the project in the reporting Financial Year (₹) | Cumulative amount spent at the end of reporting Financial Year (₹) | Status of the project - Completed / Ongoing |
|--------|------------|--|---|------------------|--|---|--|---|
| 1 | | To set up a Blood Bank in Bhavanagar, Gujarat, by the Indian Redcross Society, Bhavanagar. | 2019-20 | 2 years | 51.00 | 22.00 | 51.00 | Completed |
| | Total | | | | 51.00 | 22.00 | 51.00 | |

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year: No such case
11. Specify the reason(s), if the Company has failed to spend two per cent of the average net profit as per section 135(5): N. A. The Company has spent in excess of the required spending, as detailed above.

For Jenburkt Pharmaceuticals Ltd.

Arun R. Raskapurwala
Independent Director
(Chairman, CSR Committee)

Ashish U. Bhuta
Chairman and Managing Director.
(Member, CSR Committee)

Mumbai, 02nd June, 2021.

Annexure E

Conservation of Energy, Technology Absorption, Foreign exchange earnings and outgo:

[Particulars pursuant to Section 134(3)(m) of the Companies Act, 2013 read with Rule (8)(3) of Companies (Accounts) Rules, 2014 and forming part of the Directors' Report, for the financial year ended on 31st March, 2021.]

(A) Conservation of energy:

- i. **The steps taken or impact on conservation of energy.**
 - a. Upgradation and improvement in Plant electrical system is underway as suggested by Plant electrical system audit.
- ii. **The steps taken by Company to utilise alternate source of energy.**
 - a. New set of 2 Diesel operated electrical generating units was installed to enhance back up power capacity.
 - b. New steam boiler has been installed having better operating parameters.
- iii. **The capital investment on energy conservation equipments:**
 - a. 2 D.G sets
 - b. 1 new Boiler set.

(B) Technology absorption, adoption and innovation:

- i. **Efforts in brief made towards technology absorption.**
 - a. Continued improvement in existing products and development of new products and processes.
- ii. **The benefits derived like product improvement, cost reduction, product development or import substitution.**
 - a. Continued compliance to national and international drug regulatory agencies.
- iii. **The details of imported technology (imported during last 3 years)**
 - a. The details of technology imported : NIL
 - b. The year of import : NIL
 - c. Whether the technology been fully absorbed : NIL
 - d. If not fully absorbed, areas where absorption has not taken place and the reasons thereof : NIL
- iv. **The expenditure incurred on research and development.**

Capital Expenditure: Nil, Recurring Expenditure: 108.08 lac.
- v. **Foreign exchange earnings and outgo.**

During the year under review, the foreign exchange earnings by the Company was 2,144.38 lacs and the foreign exchange expenditure of the Company was 314.90 lac (including 0.24 lac towards dividend on equity shares).

For and on behalf of the Board of Directors

Ashish U. Bhuta
Chairman and Managing Director

Mumbai, 02nd June, 2021

Annexure F

| Sr. No. | Director / Key Managerial Personnel | Remuneration for the Year 2020-21 (₹ in Lacs) | Percentage increase in Remuneration in 2020-21 | Ratio of remuneration to median remuneration |
|---------|-------------------------------------|---|--|--|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

Mumbai, 02nd June, 2021.



Corporate Governance Report

Corporate Governance Report

| Name of the Director | Category of directorship / designation | No. of Board meetings in F.Y. 2020-21 | | Attendance at last AGM held by OAVM | No. of directorships held in another Company |
|----------------------|--|---------------------------------------|----------|-------------------------------------|--|
| | | Held | Attended | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Name of director | Category of directorship | No. of Meetings in F.Y. 2020-21 | |
|------------------|--------------------------|---------------------------------|----------|
| | | Held | Attended |
| | | | |
| | | | |
| | | | |
| | | | |

| Name of director | Category of directorship | No. of Meetings in F.Y. 2020-21 | |
|------------------|--------------------------|---------------------------------|----------|
| | | Held | Attended |
| | | | |
| | | | |
| | | | |


| Name of director | Remuneration including salary, perquisites and all benefits (₹) | Sitting fees (₹) | Total (₹) | Present service contract | No. of equity shares held as on 31 st March 2021 |
|------------------|---|------------------|-----------|--------------------------|---|
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Name of director | Category of directorship | No. of Meetings in F.Y. 2020-21 | |
|------------------|--------------------------|---------------------------------|----------|
| | | Held | Attended |
| | | | |
| | | | |
| | | | |

| Financial Year | Venue | Date | Time | Special resolutions passed |
|----------------|-------|------|------|----------------------------|
| | | | | |
| | | | | |
| | | | | |

| | |
|--|--|
| AGM: Date and Timing | |
| Financial calendar (Proposed) for F.Y. 2021-22. | |
| Cut-off date | |
| Date of book closure | |
| Expected date of dividend payment | |
| Listing of equity shares on Stock Exchange | |
| Stock Code | |
| Security ISIN No. | |
| Company's Registration No. | |

| 2020-2021 | Company's share price | | BSE Sensex | |
|-----------|-----------------------|---------|------------|-----|
| | High (₹) | Low (₹) | High | Low |
| Month | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |



| | |
|---|--|
| Details of RTA | |
| Share Transmission and Dematerialisation System | |

| Sr. No. | Category | No. of Shares held | % of shareholding |
|---------|----------|--------------------|-------------------|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| No. of Equity Shares held | No. of Shareholders | % of Shareholders | No. of Shares | % of Shareholding |
|---------------------------|---------------------|-------------------|---------------|-------------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| Type of Shareholding | No. of Share holders | % of Share-holders | No. of Shares | % of Shareholding |
|----------------------|----------------------|--------------------|---------------|-------------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| | |
|--|--|
| Dematerialisation of equity shares and liquidity | |
| Plant Location | |
| Investor correspondence be addressed to | |

| Sr. No. | Name of the policy / code and other items along with respective weblink |
|---------|---|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Certificate on Corporate Governance





Auditors' Report

Independent Auditors' Report

| Sr.No. | Key Audit Matter | Auditors Response |
|--------|------------------|-------------------|
| | | |
| | | |

| | | |
|--|--|--|
| | | |
|--|--|--|

Annexure-A to the Independent Auditors' Report

Annexure-B to the Independent Auditors' Report

| Statute | Amount (₹ in lac) | Period |
|---------|-------------------|--------|
| | | |
| | | |
| | | |

| Statute | Nature of Dues | Amount (₹ in lac) | Period | Forum where dispute is pending |
|---------|----------------|-------------------|--------|--------------------------------|
| | | | | |
| | | | | |





Financial Statements

Balance Sheet as at 31st March, 2021

| Particulars | Note | 31/03/2021 | 31/03/2020 |
|-------------|------|------------------|------------|
| | | 850.69 | |
| | | 156.22 | |
| | | 0.14 | |
| | | 47.96 | |
| | | 37.76 | |
| | | 650.07 | |
| | | 8.14 | |
| | | 2,285.78 | |
| | | 9.10 | |
| | | 758.15 | |
| | | 25.22 | |
| | | 1,400.07 | |
| | | 249.37 | |
| | | 5,401.31 | |
| | | 11.15 | |
| | | 29.95 | |
| | | 116.92 | |
| | | 12,038.00 | |
| | | 458.94 | |
| | | 9,387.69 | |
| | | 93.97 | |
| | | 296.47 | |
| | | 8.32 | |
| | | 41.66 | |
| | | 371.06 | |
| | | 2.66 | |
| | | 358.56 | |
| | | 650.95 | |
| | | 227.02 | |
| | | 127.29 | |
| | | 13.41 | |
| | | 12,038.00 | |

Statement of Profit & Loss for the year ended 31st March, 2021

| Particulars | Note | 31/03/2021 | 31/03/2020 |
|-------------|------|------------------|------------|
| | | 10,929.42 | |
| | | 430.85 | |
| | | 11,360.27 | |
| | | 678.01 | |
| | | 2,013.43 | |
| | | 318.39 | |
| | | 3,237.71 | |
| | | 47.37 | |
| | | 203.54 | |
| | | 2,697.65 | |
| | | 9,196.11 | |
| | | 2,164.17 | |
| | | 544.50 | |
| | | 8.51 | |
| | | (39.08) | |
| | | 1,650.24 | |
| | | 219.54 | |
| | | (23.58) | |
| | | - | |
| | | - | |
| | | 195.96 | |
| | | 35.96 | |

Cash Flow Statement as on 31st March, 2021

| Particulars | Note | 31/03/2021 | 31/03/2020 |
|-------------|------|-------------------|------------|
| | | 1,650.24 | |
| | | 203.54 | |
| | | (0.17) | |
| | | 513.93 | |
| | | 47.37 | |
| | | (405.26) | |
| | | (1.82) | |
| | | (0.08) | |
| | | 19.20 | |
| | | (22.21) | |
| | | (0.69) | |
| | | 2,004.05 | |
| | | 331.72 | |
| | | 363.70 | |
| | | (11.11) | |
| | | (161.42) | |
| | | 27.17 | |
| | | 92.08 | |
| | | (117.07) | |
| | | 2,529.12 | |
| | | (583.65) | |
| | | 1,945.48 | |
| | | (114.51) | |
| | | 2.97 | |
| | | (93.28) | |
| | | 72.06 | |
| | | (10,909.16) | |
| | | 8,782.59 | |
| | | 9.53 | |
| | | 369.88 | |
| | | 1.82 | |
| | | (1,878.10) | |
| | | (34.83) | |
| | | 14.42 | |
| | | - | |
| | | (51.00) | |
| | | (71.41) | |
| | | (4.03) | |
| | | 253.40 | |
| | | 249.37 | |
| | | (4.03) | |

Statement of Changes in Equity

| Particulars | Reserves & Surplus | | | Equity Instrument through OCI | Other Income of OCI | Total |
|-------------|--------------------|----------------------------|-------------------|-------------------------------|---------------------|-------|
| | Other Reserves | Capital Redemption Reserve | Retained Earnings | | | |
| | 334.62 | 5.99 | 7,440.83 | | | |
| | - | - | - | | | |
| | - | - | - | | | |
| | - | - | 1,650.24 | | | |
| | - | - | - | | | |
| | - | - | - | | | |
| | 334.62 | 5.99 | 9,091.07 | | | |

| Particulars | Reserves & Surplus | | | Equity Instrument through OCI | Other Income of OCI | Total |
|-------------|--------------------|----------------------------|-------------------|-------------------------------|---------------------|-------|
| | Other Reserves | Capital Redemption Reserve | Retained Earnings | | | |
| | 334.62 | 5.99 | 6,941.57 | | | |
| | - | - | - | | | |
| | - | - | - | | | |
| | - | - | 1,486.96 | | | |
| | - | - | (1,012.49) | | | |
| | - | - | 12.00 | | | |
| | - | - | 12.80 | | | |
| | 334.62 | 5.99 | 7,440.83 | | | |

Significant Accounting Policies

| Particular | Depreciation |
|------------|--------------|
| | |

| Particular | Depreciation |
|------------|--------------|
| | |
| | |
| | |

| Sales | 2020-21 (₹) | 2019-20 (₹) |
|-------|-------------|-------------|
| | | |

Notes forming part to Balance Sheet as at 31st March, 2021

| Particulars | Factory Building | Office Building* | Godown Building | Plant & Equipment | | Furniture & Fixtures | Electrical Fixtures | Computers | Office Equipment | Vehicle | Total |
|--|------------------|------------------|-----------------|-------------------|-------|----------------------|---------------------|-----------|------------------|---------|--------|
| | | | | General | R&D | | | | | | |
| At cost or deemed cost | | | | | | | | | | | |
| | | | | | | | | | | | |
| Accumulated depreciations and impairment | | | | | | | | | | | |
| | | | | | | | | | | | |
| Carrying Amount | | | | | | | | | | | |
| As at March 31, 2020 | 310.49 | 203.65 | 3.74 | 196.65 | 54.23 | 22.86 | 3.90 | 56.00 | 12.02 | 26.46 | 890.00 |
| As at March 31, 2021 | 290.38 | 193.14 | 3.63 | 214.80 | 44.64 | 18.65 | 11.24 | 37.21 | 9.66 | 27.34 | 850.69 |

| Particulars | Right to Use Asset | | | Goodwill | Intangible Asset | | | Capital WIP | |
|---|--------------------|----------|--------|----------|------------------|----------|-------|-------------|-------|
| | Land# | Building | Total | | Trademark | Computer | Total | | |
| At cost or deemed cost | | | | | | | | | |
| | | | | | | | | | |
| Accumulated amortisation and impairment | | | | | | | | | |
| | | | | | | | | | |
| Carrying Amount | | | | | | | | | |
| As at March 31, 2020 | | 30.83 | 167.68 | 198.51 | 0.14 | 10.36 | 73.77 | 84.13 | 11.81 |
| As at March 31, 2021 | | 30.46 | 125.76 | 156.22 | 0.14 | 7.71 | 40.24 | 47.96 | 37.76 |

| Particulars | As at 31 st March, 2021 | | | As at 31 st March, 2020 | | | Face Value |
|--|------------------------------------|---------------|---------------|------------------------------------|--------------|------|------------|
| | Units | Market Value | Cost | Units | Market Value | Cost | |
| Investments measured at Amortised Cost | | | | | | | |
| | 3,012 | 35.24 | 30.12 | | | | |
| | | 35.24 | 30.12 | | | | |
| Investments measured at Fair Value through Other Comprehensive Income | | | | | | | |
| | 1,366 | 1.01 | 1.06 | | | | |
| | 151 | 0.00 | 0.10 | | | | |
| | 10,000 | 149.36 | 0.21 | | | | |
| | 550 | 3.20 | 1.29 | | | | |
| | 200 | 0.08 | 0.24 | | | | |
| | 500 | 0.24 | - | | | | |
| | 2,000 | 0.24 | 0.47 | | | | |
| | 500 | 0.28 | 1.11 | | | | |
| | 150 | 0.01 | 0.47 | | | | |
| | 130 | 0.61 | 0.83 | | | | |
| | 5 | 4.11 | 0.30 | | | | |
| | 4,222 | 4.49 | 2.18 | | | | |
| | 1,500 | 3.23 | 2.09 | | | | |
| | 24 | 0.26 | 0.08 | | | | |
| | 372 | 7.45 | 1.90 | | | | |
| | 62 | 0.29 | - | | | | |
| | 500 | 0.15 | 1.10 | | | | |
| | 3,519 | 0.48 | 0.00 | | | | |
| | 30,000 | 11.46 | 8.73 | | | | |
| | | 186.95 | 22.17 | | | | |
| Investments measured at Fair Value through Other Comprehensive Income | | | | | | | |
| | 23,298 | 26.03 | 23.81 | | | | |
| | 2,849 | 26.68 | 20.00 | | | | |
| | 2,500 | 0.36 | 0.25 | | | | |
| | 19,382 | 57.04 | 41.36 | | | | |
| | 70,352 | 47.39 | 36.53 | | | | |
| | 18,270 | 31.00 | 23.17 | | | | |
| | 1,70,320 | 76.58 | 57.93 | | | | |
| | 1,22,231 | 39.33 | 31.50 | | | | |
| | 89,130 | 40.70 | 31.79 | | | | |
| | 37,403 | 0.02 | - | | | | |
| | 37,403 | - | - | | | | |
| | 37,403 | 23.00 | 21.72 | | | | |
| | 1,60,074 | 64.87 | 53.00 | | | | |
| | | 433.00 | 341.06 | | | | |
| | | 650.07 | 393.35 | | | | |

| | As at 31 st March, 2021 | As at 31 st March, 2020 |
|--|------------------------------------|------------------------------------|
| | 8.14 | |
| | 8.14 | |

| | | |
|--|----------|--|
| | 2261.96 | |
| | 23.81 | |
| | 2,285.78 | |

| | | |
|--|------|--|
| | 9.10 | |
| | - | |
| | 9.10 | |

| | | |
|--|--------|--|
| | 169.00 | |
| | 148.44 | |
| | 44.64 | |
| | 117.89 | |
| | 272.31 | |
| | 5.87 | |
| | 758.15 | |

| Particulars | As at 31 st March, 2021 | | | As at 31 st March, 2020 | | |
|---|------------------------------------|--------------|-------|------------------------------------|--------------|------|
| | Units | Market Value | Cost | Units | Market Value | Cost |
| Investments measured at Fair Value through Other Comprehensive Income | | | | | | |
| | 1,249 | 1.40 | 1.31 | | | |
| | 8,090 | 3.28 | 1.99 | | | |
| | - | - | - | | | |
| | - | - | - | | | |
| | - | - | - | | | |
| | - | 4.67 | 3.30 | | | |
| | - | - | - | | | |
| | 411 | 20.54 | 20.00 | | | |
| | | 20.54 | 20.00 | | | |
| | | 25.22 | 23.31 | | | |

| | As at 31 March, 2021 | As at 31 March, 2020 |
|--|----------------------|----------------------|
| | 1,400.07 | |
| | 30.08 | |
| | (30.08) | |
| | 1,400.07 | |

| | As at 31 st March, 2021 | As at 31 st March, 2020 |
|--|------------------------------------|------------------------------------|
| | 109.93 | |
| | 126.75 | |
| | 11.43 | |
| | 1.26 | |
| | 249.37 | |

| | | |
|--|----------|--|
| | 70.53 | |
| | 3,389.55 | |
| | 373.17 | |
| | 1,536.60 | |
| | 31.47 | |
| | 5,330.78 | |
| | 5,401.31 | |

| | | |
|--|-------|--|
| | 11.15 | |
| | 11.15 | |

| | | |
|--|-------|--|
| | 0.53 | |
| | 10.94 | |
| | 18.49 | |
| | 29.95 | |

| | | |
|--|--------|--|
| | 20.83 | |
| | - | |
| | 3.50 | |
| | 38.80 | |
| | 10.21 | |
| | - | |
| | 43.58 | |
| | - | |
| | 116.92 | |

| | | |
|--|----------|--|
| | 1,000.00 | |
| | 458.94 | |
| | - | |
| | 458.94 | |

| | As at 31 March, 2021 | As at 31 March, 2020 |
|--|----------------------|----------------------|
| | No. of Shares | No. of Shares |
| | 45,89,378 | |
| | - | |
| | 45,89,378 | |

| | As at 31 st March, 2021 | | As at 31 st March, 2020 | |
|--|------------------------------------|--------|------------------------------------|--------|
| | No. of Shares | % held | No. of Shares | % held |
| | 6,10,324 | 13 | | |
| | 2,61,127 | 6 | | |
| | 5,36,480 | 12 | | |
| | 3,99,700 | 9 | | |

| | As at 31 March, 2021 | As at 31 March, 2020 |
|--|----------------------|----------------------|
| | 5.99 | |
| | - | |
| | | 5.99 |
| | 334.62 | |
| | - | |
| | | 334.62 |
| | 7,440.83 | |
| | 1,650.24 | |
| | - | |
| | - | |
| | - | |
| | | 9,091.07 |
| | (239.95) | |
| | 246.60 | |
| | (27.05) | |
| | - | |
| | (23.58) | |
| | | (43.99) |
| | | 9,387.69 |

| | | |
|--|-------|--|
| | 93.97 | |
| | 93.97 | |

| | | |
|--|--------|--|
| | 296.47 | |
| | 296.47 | |

| | As at 31 st March, 2021 | As at 31 st March, 2020 |
|--|------------------------------------|------------------------------------|
| | (23.82) | |
| Deferred tax Assets / (Liabilites) recognised in Profit & Loss in relation to | | |
| | (69.28) | |
| | 32.04 | |
| | 7.57 | |
| | (0.14) | |
| | 68.89 | |
| | 39.08 | |
| Deferred tax Assets / (Liabilites) recognised in Other Comprehensive Income in relation to | | |
| | (23.58) | |
| | (23.58) | |
| | (8.32) | |
| | (52.32) | |
| | 34.13 | |
| | (0.14) | |
| | (0.23) | |
| | (29.37) | |
| | 17.36 | |
| | 14.67 | |
| | 7.57 | |
| | (8.32) | |
| | 41.66 | |
| | 41.66 | |
| | 371.06 | |
| | - | |
| | 371.06 | |
| | - | |
| | 2.66 | |
| | - | 2.66 |
| | 52.60 | |
| | 68.60 | |
| | 237.36 | 358.56 |
| | | 361.23 |

| | As at 31 st March, 2021 | As at 31 st March, 2020 |
|--|------------------------------------|------------------------------------|
| | - | |
| | 70.53 | |
| | 580.43 | |
| | 650.95 | |
| | 106.40 | |
| | 120.62 | |
| | 227.02 | |
| | 58.30 | |
| | 68.99 | |
| | 127.29 | |
| | 10.18 | |
| | 1.87 | |
| | 0.18 | |
| | 7.70 | |
| | 0.05 | |
| | - | |
| | - | |
| | (6.57) | |
| | 13.41 | |
| | 44.05 | |
| | 544.50 | |
| | 575.14 | |
| | 13.41 | |

Schedules forming part of Profit & Loss Account for the year ended on 31st March 2021

| | As at 31 st March, 2021 | As at 31 st March, 2020 |
|--|--|------------------------------------|
| | 10,886.84 42.58 10,929.42 | |
| | 401.08 2.11 2.07 405.26 1.82 22.21 - 0.17 - 0.01 0.07 0.65 0.13 0.54 430.85 | |
| | 216.12 393.81 - 609.93 169.00 440.93 114.65 270.87 385.52 148.44 237.08 678.01 | |
| | 2,013.43 2,013.43 | |
| | 44.64 117.89 272.31 5.87 13.72 193.91 548.14 3.33 (30.92) 76.02 275.84 (2.54) 318.39 | |

| | As at 31 st March, 2021 | As at 31 st March, 2020 |
|--|---|------------------------------------|
| | 2,861.38 360.39 15.94 3,237.71 | |
| | 42.41 4.96 47.37 | |
| | 203.54 203.54 | |
| | 49.89 34.47 0.09 128.69 149.87 354.97 1,203.64 16.60 278.71 9.40 65.97 27.27 22.01 94.82 28.29 134.49 - 98.48 2,697.65 | |
| | 5.40 2.50 1.50 9.40 | |
| | 3.89 88.43 2.53 2.63 0.69 0.02 0.30 98.48 108.08 | 9.59 |

| | As at 31 st March, 2021 | As at 31 st March, 2020 |
|--|--|------------------------------------|
| | 544.50 (39.08) 8.51 513.93 | |
| | 2,164.17 25.168 545 - 110.35 110.66 544.36 544.50 39.08 (23.58) 15.49 559.99 25.88 | |
| | 72.59 174.00 (27.05) (23.58) 195.96 | |
| | 1,650.24 45,89,378 35.96 10 | |
| | 1 3,000 0.24 | |
| | 209.35 - 23.00 - 15.36 2.87 64.09 - - 314.66 | |
| | 2,144.38 2,144.38 | |

| | As at 31 st March, 2021 | As at 31 st March, 2020 |
|--|------------------------------------|------------------------------------|
| | 72.59 | |
| | - | |
| | 22.00 | |
| | 0.23 | |
| | 94.82 | |

| Name of the Related Party | Relationship |
|---------------------------|--------------|
| | |

| | As at 31 st March, 2021 | As at 31 st March, 2020 |
|--|------------------------------------|------------------------------------|
| | - | |
| | - | |
| | - | |
| | - | |
| | 51.00 | |

| | | |
|--|--------|--|
| | 147.04 | |
| | 45.73 | |
| | 33.20 | |

| | | |
|--|-------|--|
| | 30.00 | |
|--|-------|--|

| | As at 31 st March, 2021 | As at 31 st March, 2020 |
|--|------------------------------------|------------------------------------|
| | 1,645.16 | |
| | 3.14 | |
| | - | |

| Particulars | As at 31 st March, 2021 | As at 31 st March, 2020 |
|-------------|---|------------------------------------|
| | 67.84 7.05 | |
| | Gratuity 01-Apr-20 31-Mar-21 12 Months | |
| | 6.87% 6.87% 7.00% 17%, 5% and 3% Category-wise Indian Assured Lives Mortality (2006-08) Ultimate N.A. | |
| | 6.80% 6.80% 7.00% 17%, 5% and 3% Category-wise Indian Assured Lives Mortality (2006-08) Ultimate N.A. | |
| | 549.20 37.73 44.16 - - - - - - (51.00) - - 3.89 21.23 605.21 | |

| Particulars | As at 31 st March, 2021 | As at 31 st March, 2020 |
|-------------|------------------------------------|------------------------------------|
| | 492.17 | |
| | 33.81 | |
| | 63.18 | |
| | - | |
| | - | |
| | (51.00) | |
| | - | |
| | - | |
| | - | |
| | (1.93) | |
| | 536.22 | |
| | (605.21) | |
| | 536.22 | |
| | (68.99) | |
| | (68.99) | |
| | 549.20 | |
| | (492.17) | |
| | 57.03 | |
| | 37.73 | |
| | (33.81) | |
| | 3.92 | |
| | 44.16 | |
| | 3.92 | |
| | - | |
| | - | |
| | - | |
| | - | |
| | 48.08 | |
| | 25.12 | |
| | 1.93 | |
| | - | |
| | 27.05 | |
| | 57.03 | |
| | 48.08 | |
| | 27.05 | |
| | - | |
| | - | |
| | - | |
| | (63.18) | |
| | 68.99 | |

| Particulars | As at 31 st March, 2021 | As at 31 st March, 2020 |
|-------------|------------------------------------|------------------------------------|
| | - | |
| | - | |
| | - | |
| | - | |
| | - | |
| | 536.22 | |
| | - | |
| | - | |
| | 536.22 | |
| | 731 | |
| | 111.77 | |
| | 11 | |
| | 13 | |
| | 605.21 | |
| | 111.77 | |
| | 605.21 | |
| | (536.22) | |
| | 68.99 | |
| | 41.15 | |
| | (36.46) | |
| | 4.69 | |
| | 55.59 | |
| | 4.69 | |
| | - | |
| | 56.98 | |
| | 58.74 | |
| | 36.46 | |
| | 39.99 | |
| | 31.46 | |
| | 41.93 | |
| | 230.60 | |
| | 907.47 | |
| | 605.21 | |
| | (51.65) | |
| | 60.67 | |
| | 58.45 | |
| | (50.69) | |
| | (2.21) | |
| | 2.35 | |

| Particulars | As at 31 st March, 2021 | | | As at 31 st March, 2020 | | |
|-------------|--|------------------------------------|----------------|--|------------------------------------|----------------|
| | Fair Value through other comprehensive Income Amount | Fair Value through Profit and Loss | Amortised Cost | Fair Value through other comprehensive Income Amount | Fair Value through Profit and Loss | Amortised Cost |
| | 624.62 | 20.54 | 30.12 | | | |
| | | | 1,400.07 | | | |
| | | | 249.37 | | | |
| | | | 5,401.31 | | | |
| | | | 19.30 | | | |
| | | | 2,315.73 | | | |
| | | | 135.63 | | | |
| | | | 371.06 | | | |
| | | | 361.23 | | | |
| | | | 947.42 | | | |

| Particulars | As at 31 st March, 2021 | Fair Value Measurement at the end of the reporting period | | | As at 31 st March, 2020 | Fair Value Measurement at the end of the reporting period | | |
|-------------|------------------------------------|---|---------|---------|------------------------------------|---|---------|---------|
| | | Level 1 | Level 2 | Level 3 | | Level 1 | Level 2 | Level 3 |
| | 624.62 | 624.62 | - | - | | | | |
| | 20.54 | 20.54 | - | - | | | | |

| Movement in the expected credit loss allowance on trade receivables | For the year ended 31 st March 2021 | For the year ended 31 st March 2020 |
|---|--|--|
| | 10.88 | |
| | 19.20 | |
| | - | |
| | - | |
| | 30.08 | |

| Particulars | Less than 1 year | 1-3 years | More than 3 years | As at 31 st March 2021 |
|-------------|------------------|-----------|-------------------|-----------------------------------|
| | | | | |

| Particulars | Less than 1 year | 1-3 years | More than 3 years | As at 31 st March 2020 |
|-------------|------------------|-----------|-------------------|-----------------------------------|
| | | | | |

| Particulars | US \$ (converted in ₹) | Euro (converted in ₹) | Total as at 31 st March 2021 (in ₹) | US \$ (converted in ₹) | Euro (converted in ₹) | Total as at 31 st March 2021 (in ₹) |
|-------------|------------------------------|-----------------------------|--|------------------------------|-----------------------------|--|
| | 344.16 1.26 | 336.82 - | 680.98 1.26 | | | |
| | 16.8 255.74 | 93.75 115.32 | 110.55 371.06 | | | |

| | As at 31 st March 2021 Amount (₹) | As at 31 st March 2020 Amount (₹) |
|--|---|---|
| | 30.12 645.17 | |

Financial Highlights

(₹ in Lac)

| Description | 2020-21 (IND-AS) | 2019-20 (IND-AS) | 2018-19 (IND-AS) | 2017-18 (IND-AS) | 2016-17 (IND-AS) | 2015-16 | 2014-15 | 2013-14 | 2012-13 | 2011-12 |
|---|---------------------|---------------------|---------------------|---------------------|---------------------|----------|----------|----------|----------|----------|
| PROFIT & LOSS ACCOUNT | | | | | | | | | | |
| Revenue from operations | 10,929.42 | 11,889.09 | 12,264.43 | 11,467.42 | 10,330.60 | 9,429.95 | 8,634.02 | 7,737.97 | 7,043.03 | 6,068.28 |
| Other Income | 430.85 | 421.83 | 340.97 | 339.40 | 295.52 | 337.77 | 226.48 | 163.62 | 141.47 | 123.53 |
| Gross Revenues /Income | 11,360.27 | 12,310.92 | 12,605.40 | 11,806.82 | 10,626.12 | 9,767.72 | 8,860.50 | 7,901.59 | 7,184.50 | 6,191.81 |
| Profit before depreciation, interest and tax (PBDIT) | 2,415.08 | 2,396.27 | 2,837.23 | 2,718.13 | 2,267.60 | 1,919.81 | 1,735.55 | 1,314.69 | 1,124.47 | 1,030.74 |
| Profit before Tax | 2,164.17 | 2,113.78 | 2,663.34 | 2,526.89 | 2,047.89 | 1,682.83 | 1,434.00 | 1,032.88 | 882.38 | 852.06 |
| Profit after Tax (PAT) | 1,650.24 | 1,486.96 | 1,979.78 | 1,721.22 | 1,350.77 | 1,077.90 | 964.92 | 750.63 | 621.53 | 599.52 |
| Dividend & dividend distribution tax | 468.12 | 1,012.49 | 331.97 | 618.97 | - | 402.90 | 352.53 | 275.58 | 226.94 | 190.39 |
| Dividend () on 10/- paid-up | 10.20 | 8.10 | 10.20 | 9.00 | 8.10 | 7.20 | 6.30 | 5.10 | 4.20 | 3.50 |
| Balance Sheet | | | | | | | | | | |
| Share Capital | 458.94 | 458.94 | 458.94 | 458.94 | 464.93 | 464.93 | 464.93 | 464.93 | 464.93 | 464.93 |
| Reserves & Surplus | 9,387.69 | 7,541.49 | 7,287.61 | 5,667.09 | 4,978.74 | 3,553.94 | 2,878.94 | 2,265.73 | 1,800.17 | 1,405.58 |
| Net worth | 9,846.63 | 8,000.43 | 7,746.55 | 6,126.03 | 5,443.67 | 4,018.87 | 3,343.87 | 2,730.66 | 2,265.10 | 1,870.51 |
| Deferred Tax Liability | (8.32) | 23.82 | (36.81) | 11.79 | 50.27 | 63.14 | 76.25 | 119.68 | 112.00 | 115.15 |
| Long Term Loans / Provision | 390.44 | 426.46 | 274.38 | 302.39 | 316.86 | 312.51 | 269.92 | 261.23 | 252.73 | 481.40 |
| Capital Employed (A+B+E): | 7,292.30 | 8,158.79 | 7,763.41 | 6,242.05 | 5,621.67 | 4,333.21 | 3,625.57 | 3,595.15 | 3,113.70 | 2,643.46 |
| Net fixed assets (A) | 1,055.01 | 1,172.79 | 959.18 | 956.83 | 1,062.64 | 1,210.65 | 1,160.45 | 1,357.05 | 1,422.64 | 1,312.01 |
| Capital Work in Progress (B) | 37.76 | 11.81 | 99.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 23.87 |
| Current Assets (C) | 7,992.14 | 8,954.27 | 8,966.79 | 6,592.16 | 6,388.60 | 4,530.93 | 4,860.35 | 3,818.06 | 3,441.36 | 2,643.60 |
| Current Liabilities (D) | 1,792.61 | 1,980.08 | 2,261.56 | 1,306.94 | 1,829.57 | 1,408.37 | 2,395.23 | 1,579.96 | 1,750.30 | 1,336.02 |
| Net Current Assets (C-D)= (E) | 6,199.53 | 6,974.19 | 6,705.23 | 5,285.22 | 4,559.03 | 3,122.56 | 2,465.12 | 2,238.10 | 1,691.06 | 1,307.58 |
| Investments | 650.07 | 249.67 | 185.61 | 162.82 | 138.64 | 61.32 | 31.21 | 31.21 | 31.21 | 52.80 |
| Ratio & Statistics | | | | | | | | | | |
| PBDIT as % of gross revenue | 21.26 | 19.46 | 22.51 | 23.02 | 21.34 | 20.36 | 20.10 | 16.99 | 15.97 | 16.99 |
| PAT as % of gross revenue | 14.53 | 12.08 | 15.70 | 14.58 | 12.71 | 11.43 | 11.18 | 9.70 | 8.82 | 9.88 |
| ROCE % | 22.75 | 18.25 | 25.50 | 27.57 | 24.03 | 24.88 | 26.61 | 20.88 | 19.96 | 22.89 |
| RONW % | 16.76 | 18.59 | 25.56 | 28.10 | 24.81 | 26.82 | 28.86 | 27.49 | 27.44 | 32.05 |
| Current Ratio | 4.46 | 4.52 | 3.96 | 5.04 | 3.49 | 3.22 | 2.03 | 2.42 | 1.97 | 1.98 |
| Earning per share () | 35.96 | 32.40 | 43.14 | 37.50 | 29.05 | 23.18 | 20.75 | 16.15 | 13.37 | 12.89 |
| Book Value per equity share () | 158.90 | 177.78 | 168.79 | 133.49 | 117.09 | 86.44 | 71.92 | 58.73 | 48.72 | 40.23 |

Jenburkt Pharmaceuticals Limited

Nirmala Apartments, 93, Jayprakash Road,
Andheri (West), Mumbai-400058.

Tel.:+91-22-66943121, Fax:+91-22-66943127,
Email: investor@jenburkt.com • Web: www.jenburkt.com